Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Operating free cash flow and margin OFCF of +21% driven by higher OP, net of cash adjustments and NWC movements Roche 38.8% % of sales 33.6% 30.3% 26.4% 23.5% +5.5%p¹ 17.2% +4.0%p¹ CHFM 1 At CER=Constant Exchange Rates 5,036 +21%¹ 9,782 8,117 2020 2021 2022 Roche Group -0.7% 13.0% 15.2% +2.1%p¹ +20%¹ 8,667 7,282 5,454 -44 Pharma Division +29%¹ 1,178 1,509 Diagnostics Division 50 63

View entire presentation